Theme: Lab to Industry as Biosignatures to Therapeutic Discovery
Dates: August 31-September 02, 2015
Email id: firstname.lastname@example.org
Venue: Toronto, Canada
Conference URL: http://www.omicsgroup.com/biomarkers-clinical-research-conference-2015/
Treatment efficacy for diseases and disorders prioritize the diagnosis and prognosis accuracy; molecular marking being the next step. Team Biomarkers opens up the 6th chapter and call upon the medical, clinical and life science researchers towards taking the biomolecular signature set to a probable therapeutic discovery. The thematic blend of past scientific conferences has uplayered the importance of taking the Laboratory research to the industry. Biomarkers-2015 will have the theme “Lab to Industry as Biosignatures to Therapeutic Discovery”. Biomarkers-2015 is aiming to ground healthcare industry developers, academic researchers and organizational scientists from the expertise of Biomarkers Development to help pave the needed scientific avenue for the productive information exchange towards technological advancements.
Biomarkers-2015 International conference intends to ground the disciplines likes chemical & biological sciences, applied life sciences into computational & statistical analysis, genomics & proteomics, analytical & biophysical and microarray technologies to put forth the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis.
Primary research areas of focus at the conference are types & approaches for biomarker discovery, proteomic biomarkers, cytogenetic biomarkers, SNP biomarkers, molecular imaging biomarkers, microarray data analysis, clinical & non-clinical biomarkers, diagnostic biomarkers, biomarkers for disorder, clinical research & development, biomarkers of exposure, response, and susceptibility and microbial infections. The importance of each of the research area is appended to the theme at the scientific meeting. Histological studies of the pathogenic or diseased tissue are carried out for protein biomarkers and cytogenetic biomarkers. Genome mapping of the diseased DNA is studied in reference to the standard sequence in the databae, the study comprised the principles of comparative genomics. The unique genetic variants can be utilized as SNP biomarkers which are identified as genetic signatures. The polymorphisms like that of Single Nucleotides also add into it. Fluorescent Staining of paraffin waxed solid tumour is quite a popular method for detection and the development of imaging biomarkers with quantitative specificity majorly used at stage determination of the disease condition. Histochemical studies comprising the disease immunology has an added advantage of diagnostic specificity. DNA microarray studies resulted from combinatorial statistical approaches towards discovering the significant genes has generated the biomarkers of data analysis; this has helped to converge the sample space to be tested. Testifying the molecular signature towards clinical outcomes justifies the clinical biomarkers and those not justified are non clinical biomarkers. Confirming a disease and its condition is the diagnosis and molecular set utilized towards confirmation is diagnostic biomarker; the concept when applies to the treatment methodology is the prognostic biomarker.